LY2334737 (C007B-364285)

LY2334737 is an nucleoside analog and is an orally active proagent of Gemcitabine. LY2334737 exhibits inhibitory activity against enterovirus A71 (EV-A71) infection . LY2334737 has antiviral and anticancer effectsIn VitroFive cell lines that express CES2 responded to LY2334737 treatment. LY2334737 is less cytotoxic to a SK-OV-3 CES2 knockdown than parental cells. The drug response of CES2-transfected HCT-116 cells correlated with CES2 expression level. Bystander studies show statistically greater PC-3-GFP growth inhibition by LY2334737 when cells are cocultured with CES2 and not mock transfectants. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoOral treatment of xenograft models with 3.2 mg/kg LY2334737 once a day for 21 days shows greater tumor growth inhibition of CES2 transfectant than the mock transfectant . Metronomic LY2334737 administration causes increased blood flow in luciferase-tagged LM2-4 tumor xenografts, and this effect, readily measured using contrast micro-ultrasound, coincided with a relative increase in tumor bioluminescence. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:Enterovirus A71 (EV-A71). Specification: 0.98 Molecular Formula: C17H25F2N3O5 Molecular Weight: 389.39 PubChem CID: 11646777 Isomeric SMILES: CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F